Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies.
Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies.
复制标题
DOI：
10.1016/j.clcc.2015.10.002
复制
发表时间：
2016-03
影响因子：
3.4
通讯作者：
Flowers CR
中科院分区：
文献类型：
--
作者：
Goldstein DA;Zeichner SB;Bartnik CM;Neustadter E;Flowers CR
从美国付款人的角度评估转移性结直肠癌 (mCRC) 治疗策略的成本效益。我们根据预先指定的搜索标准，对已发表的转移性结直肠癌治疗策略的成本效益分析进行了系统回顾。我们确定了 14 篇符合我们搜索标准的论文，并揭示了当前治疗策略的不同程度的价值。 5FU、伊立替康和奥沙利铂等较老的药物可提供高价值的治疗。更现代的针对 EGFR 或 VEGF 途径的药物，例如贝伐珠单抗、西妥昔单抗和帕尼单抗，以目前的成本来看似乎并不是具有成本效益的治疗方法。论文中使用的分析方法差异很大，并且可能在增量成本效益比的异质性中发挥着重要作用。目前转移性结直肠癌治疗策略的成本效益差异很大。美国联邦药物管理局 (FDA) 最近批准的用于治疗转移性结直肠癌的药物并不具有成本效益，这主要是由高昂的药物成本驱动的。
To evaluate, from a US payer perspective, the cost-effectiveness of treatment strategies for metastatic colorectal cancer (mCRC). We performed a systematic review of published cost-effectiveness analyses of treatment strategies for mCRC with pre-specified search criteria. We identified 14 papers that fulfilled our search criteria and revealed varying levels of value amongst current treatment strategies. Older agents such as 5FU, irinotecan, and oxaliplatin provide high value treatments. More modern agents targeting the EGFR or VEGF pathways, such as bevacizumab, cetuximab and panitumumab do not appear to be cost effective treatments at their current costs. The analytical methods used within the papers varied widely, and likely plays a significant role in the heterogeneity in incremental cost effectiveness ratios. The cost-effectiveness of current treatment strategies for mCRC is highly variable. Drugs recently approved by the Federal Drug Administration (FDA) for mCRC are not cost-effective, and this is primarily driven by high drug costs.